US Patent

US8093295 — Formulations of suberoylanilide hydroxamic acid and methods for producing the same

Formulation · Assigned to Merck Sharp and Dohme LLC · Expires 2026-05-16 · 0y expired

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of suberoylanilide hydroxamic acid, also known as Zolinza, with specific properties and a process for producing them.

USPTO Abstract

The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.

Drugs covered by this patent

Patent Metadata

Patent number
US8093295
Jurisdiction
US
Classification
Formulation
Expires
2026-05-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.